HEALTHSTREAM INC Income Taxes Disclosure
9. INCOME TAXES
Components of income before income taxes are as follows (in thousands):
| Year Ended December 31, | ||||||||||||
| 2025 | 2024 | 2023 | ||||||||||
| United States | $ | 23,618 | $ | 25,201 | $ | 18,472 | ||||||
| Foreign | (400 | ) | (398 | ) | 39 | |||||||
| Income before income tax provision | $ | 23,218 | $ | 24,803 | $ | 18,511 | ||||||
The provision for income taxes is comprised of the following (in thousands):
| Year Ended December 31, | ||||||||||||
| 2025 | 2024 | 2023 | ||||||||||
| Current federal | $ | (794 | ) | $ | 4,712 | $ | 4,066 | |||||
| Current state | 536 | 1,184 | 942 | |||||||||
| Current foreign | 17 | 14 | 15 | |||||||||
| Deferred federal | 4,622 | (827 | ) | (1,493 | ) | |||||||
| Deferred state | 617 | (223 | ) | (214 | ) | |||||||
| Deferred foreign | (122 | ) | (64 | ) | (18 | ) | ||||||
| Provision for income taxes | $ | 4,876 | $ | 4,796 | $ | 3,298 | ||||||
As noted above, we adopted ASU 2023-09 on a prospective basis effective January 1, 2025. The following table presents required disclosure pursuant to ASU 2023-09 and reconciles the U.S. federal statutory tax amount and rate to our actual global effective amount and rate for the year ended December 31, 2025:
| Year Ended December 31, 2025 | ||||||||
| Amount | Percent | |||||||
| U.S. federal statutory tax rate | $ | 4,876 | 21.00 | % | ||||
| State and local income taxes, net of federal income tax effect (a) | 1,054 | 4.54 | % | |||||
| Foreign tax effects | ||||||||
| Other foreign jurisdictions(b) | (20 | ) | -0.09 | % | ||||
| Tax credits | ||||||||
| Research and development tax credits | (790 | ) | -3.40 | % | ||||
| Other adjustments | (244 | ) | -1.05 | % | ||||
| Effective tax rate | $ | 4,876 | 21.00 | % | ||||
(a) State taxes in California, Minnesota, Oregon, Pennsylvania, Tennessee, and Texas made up the majority (greater than 50%) of the tax effect in this category
(b) Includes Australia, Canada, and New Zealand
The following table presents a pre-ASU 2023-09 adoption reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying Consolidated Statements of Income is as follows (in thousands) for the years ended December 31, 2024 and 2023:
| 2024 | 2023 | |||||||
| Federal tax provision at the statutory rate | $ | 5,187 | $ | 3,887 | ||||
| State income tax provision, net of federal benefit | 710 | 528 | ||||||
| Tax credits | (1,284 | ) | (1,197 | ) | ||||
| Change in valuation allowance | 52 | 3 | ||||||
| Adjustments for prior year taxes | (36 | ) | (19 | ) | ||||
| Changes in uncertain tax positions | 160 | 167 | ||||||
| Other | 7 | (71 | ) | |||||
| Provision for income taxes | $ | 4,796 | $ | 3,298 | ||||
Management periodically assesses the realizability of its deferred tax assets, and to the extent that a recovery is not likely, a valuation allowance is established to reduce the deferred tax asset to the amount estimated to be recoverable. At December 31, 2025, the Company has a valuation allowance of $2.0 million recorded against deferred tax assets for state net operating losses and certain foreign deferred tax assets.
As of December 31, 2025, the Company had federal, state, and foreign net operating loss carryforwards of $14.4 million, $9.9 million, and $8.0 million, respectively. Certain losses have an indefinite carryforward period, while other loss carryforwards will expire in years 2032 through 2045. A portion of the net operating loss carryforwards are subject to annual limitations under Internal Revenue Code Section 382. The annual limitations could result in the expiration of net operating loss and tax credit carryforwards before they are fully utilized. The Company is subject to income taxation at the federal, foreign, and various state levels. The Company is no longer subject to U.S. federal tax examinations for tax years before 2022, and with few exceptions, the Company is not subject to examination by foreign or state tax authorities for tax years which ended before 2022. Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2022 are also subject to examination and adjustment.
A reconciliation of the beginning and ending liability for gross unrecognized tax benefits are as follows (in thousands):
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Balance at beginning of year | $ | 1,140 | $ | 1,160 | ||||
| Additions for tax positions in current year | 227 | 319 | ||||||
| Reductions for tax positions of prior years | (216 | ) | (173 | ) | ||||
| Reductions for payments for tax positions of prior years | — | (166 | ) | |||||
| Balance at end of year | $ | 1,151 | $ | 1,140 | ||||
Unrecognized tax benefits included tax positions of $1.2 million and $1.1 million for the years ended December 31, 2025 and 2024, respectively, that if recognized would impact the Company’s effective tax rate.
Significant components of deferred tax assets and deferred tax liabilities are as follows (in thousands):
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Deferred tax assets: | ||||||||
| Allowance for credit losses | $ | 368 | $ | 316 | ||||
| Accrued liabilities | 736 | 681 | ||||||
| Capitalized software development | — | 2,916 | ||||||
| Lease liability | 4,447 | 5,097 | ||||||
| Tax credits | 520 | 557 | ||||||
| Stock-based compensation | 1,239 | 1,267 | ||||||
| Deferred revenue | 1,404 | 451 | ||||||
| Net operating loss carryforwards | 5,548 | 2,595 | ||||||
| Total deferred tax assets | 14,262 | 13,880 | ||||||
| Less: Valuation allowance | (1,992 | ) | (1,900 | ) | ||||
| Deferred tax assets, net of valuation allowance | 12,270 | 11,980 | ||||||
| Deferred tax liabilities: | ||||||||
| Deductible goodwill | 8,642 | 7,796 | ||||||
| Nondeductible intangible assets | 1,538 | 1,741 | ||||||
| Right of use assets | 3,863 | 4,410 | ||||||
| Prepaid assets | 12,506 | 11,156 | ||||||
| Capitalized software development | 2,478 | — | ||||||
| Property and equipment | 1,458 | 1,425 | ||||||
| Basis difference on investments | 31 | 48 | ||||||
| Total deferred tax liabilities | 30,516 | 26,576 | ||||||
| Net deferred tax liabilities | $ | 18,246 | $ | 14,596 | ||||
We adopted ASU 2023-09 on a prospective basis for the year ended December 31, 2025 and have included the following table as a result of our adoption, which presents income taxes paid (net of refunds received) for the year ended December 31, 2025:
| Federal | $ | 960 | ||
| State | ||||
| Pennsylvania | 94 | |||
| Texas | 95 | |||
| Other States | 605 | |||
| Foreign | 18 | |||
| Income taxes, net of amounts refunded | $ | 1,772 |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 27, 2026 | Showing above |
| 2022 | Feb 28, 2023 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.